|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global Burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gu MJ, Huang QC, Bao CZ, Li YJ, Li XQ, Ye
D, Ye ZH, Chen K and Wang JB: Attributable causes of colorectal
cancer in China. BMC Cancer. 18:382018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu S, Zheng R, Zhang M, Zhang S, Sun X
and Chen W: Incidence and mortality of colorectal cancer in China,
2011. Chin J Cancer Res. 27:22–28. 2015.PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Catto JW, Alcaraz A, Bjartell AS, De Vere
White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L,
Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and
kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rabinowits G, Gerçel-Taylor C, Day JM,
Taylor DD and Kloecker GH: Exosomal microRNA: A diagnostic marker
for lung cancer. Clin Lung Cancer. 10:42–46. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lodewijk L, Prins AM, Kist JW, Valk GD,
Kranenburg O, Rinkes IH and Vriens MR: The value of miRNA in
diagnosing thyroid cancer: A systematic review. Cancer Biomark.
11:229–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
To KK, Tong CW, Wu M and Cho WC: MicroRNAs
in the prognosis and therapy of colorectal cancer: From bench to
bedside. World J Gastroenterol. 24:2949–2973. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tao Y, Ma C, Fan Q, Wang Y, Han T and Sun
C: MicroRNA-1296 facilitates proliferation, migration and invasion
of colorectal cancer cells by targeting SFPQ. J Cancer.
9:2317–2326. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lipson D, Capelletti M, Yelensky R, Otto
G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T,
Brennan KW, et al: Identification of new ALK and RET gene fusions
from colorectal and lung cancer biopsies. Nat Med. 18:382–384.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Motoyama K, Inoue H, Takatsuno Y, Tanaka
F, Mimori K, Uetake H, Sugihara K and Mori M: Over-and
under-expressed microRNAs in human colorectal cancer. Int J Oncol.
34:1069–1075. 2009.PubMed/NCBI
|
|
15
|
Bao L, Zhang M, Han S, Zhan Y, Guo W, Teng
F, Liu F, Guo M, Zhang L, Ding G and Wang Q: MicroRNA-500a promotes
the progression of hepatocellular carcinoma by
post-transcriptionally targeting BID. Cell Physiol Biochem.
47:2046–2055. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schmittgen TD, Lee EJ, Jiang J, Sarkar A,
Yang L, Elton TS and Chen C: Real-time PCR quantification of
precursor and mature microRNA. Methods. 44:31–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu K, Li L, Rusidanmu A, Wang Y and Lv X:
Down-regulation of miR-1294 is related to dismal prognosis of
patients with esophageal squamous cell carcinoma through elevating
c-Myc expression. Cell Physiol Biochem. 36:100–110. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerlier D and Thomasset N: Use of MTT
colorimetric assay to measure cell activation. J Immunol Methods.
94:57–63. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fotakis G and Timbrell JA: In vitro
cytotoxicity assays: Comparison of LDH, neutral red, MTT and
protein assay in hepatoma cell lines following exposure to cadmium
chloride. Toxicol Lett. 160:171–177. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Twentyman PR and Luscombe M: A study of
some variables in a tetrazolium dye (MTT) based assay for cell
growth and chemosensitivity. Br J Cancer. 56:279–285. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrari M, Fornasiero MC and Isetta AM:
MTT colorimetric assay for testing macrophage cytotoxic activity in
vitro. J Immunol Methods. 131:165–172. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Milella M, Falcone I, Conciatori F, Cesta
Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F and Ciuffreda L: PTEN: Multiple functions in human
malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao Y and Wang Y and Wang Y: Up-regulated
miR-500a enhances hepatocarcinoma metastasis by repressing PTEN
expression. Biosci Rep. 37(pii): BSR201708372017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Degli Esposti D, Aushev VN, Lee E, Cros
MP, Zhu J, Herceg Z, Chen J and Hernandez-Vargas H: miR-500a-5p
regulates oxidative stress response genes in breast cancer and
predicts cancer survival. Sci Rep. 7:159662017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang CJ, Mulholland DJ, Valamehr B,
Mosessian S, Sellers WR and Wu H: PTEN nuclear localization is
regulated by oxidative stress and mediates p53-dependent tumor
suppression. Mol Cell Biol. 28:3281–3289. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chalhoub N and Baker SJ: PTEN and the
PI3-kinase pathway in cancer. Annu Rev Pathol. 4:127–150. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Therkildsen C, Bergmann TK,
Henrichsen-Schnack T, Ladelund S and Nilbert M: The predictive
value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment
in metastatic colorectal cancer: A systematic review and
meta-analysis. Acta Oncol. 53:852–864. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akhmedkhanov A, Zeleniuch-Jacquotte A and
Toniolo P: Role of exogenous and endogenous hormones in endometrial
cancer: Review of the evidence and research perspectives. Ann N Y
Acad Sci. 943:296–315. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deocampo ND, Huang H and Tindall DJ: The
role of PTEN in the progression and survival of prostate cancer.
Minerva Endocrinol. 28:145–153. 2003.PubMed/NCBI
|
|
34
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Georgescu MM: PTEN tumor suppressor
network in PI3K-Akt pathway control. Genes Cancer. 1:1170–1177.
2010. View Article : Google Scholar : PubMed/NCBI
|
